Commercial ExpansionGenio commercially launched in the UK with its first implants successfully performed and also launched in the Middle East.
Market OpportunityThe target market for Genio in the U.S. is approximately 510,000 patients, representing an annual total addressable market of approximately $10 billion.
Regulatory MilestonesThe FDA has issued an Approvable Letter for Nyxoah's Genio system, indicating a positive step towards full market approval.